During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
The baseline testing was done for a trial, now in progress, to determine whether supplementing with Kemin LC’s and DSM’s FloraGLO lutein (10 mg/day) and DSM’s OptiSharp zeaxanthin (2 mg/day) leads to improved visual performance by increasing the level of macular pigment. The test tablets feature DSM’s Actilease technology to maximise the absorption of lutein and zeaxanthin.
The baseline testing results were presented in May at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale, FL.
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
The Nutritional Outlook Podcast Episode 36: Best of the Industry Service Provider, Radicle Science
December 26th 2024Nutritional Outlook's managing editor, Sebastian Krawiec, interviews Radicle Science co-founders, Pelin Thorogood and Jeff Chen, MD. Radicle Science has been selected as this year's Best of the Industry, Service Provider.